HF  Avidity Partners




     Office Locations:

2828 N. Harwood St. #1220
Dallas, TX 75201
Phone: 214-550-1822

 

Stages:

  • Early


 

Industries:

  • Life Sciences & Healthcare

  •  

    Description:

    Avidity Partners Management is a hedge fund in Dallas with $1.17B assets under management. David Witzke, a former money manager at Citadel, started the health-care focused hedge fund with about $750 million in commitments. The Dallas-based firm was co-founded by former Highland Capital Management money manager Michael Gregory.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    David Witzke Co-Founder
    Michael Gregory Co-Founder

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      10/17/2024


      Aktis Oncology


      MA


      $175,000,000


      Series B


      09/25/2024


      Helaina


      NY


      $45,000,000


      Series B


      04/25/2024


      Endeavor BioMedicines


      CA


      $132,500,000


      Series C


      12/12/2023


      Calyxo


      CA


      $50,000,000


      Series D


     

    Portfolio companies include:

     

    Recent News: